Compare Stocks → It’s now possible to know the win rate of every trade… BEFORE you take it! (From WealthPress) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AVTXNASDAQ:EVAXNASDAQ:LFLYNASDAQ:MTBC Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVTXAvalo Therapeutics$15.94+6.4%$9.42$3.95▼$1,130.40$16.42M1.15537,552 shs78,196 shsEVAXEvaxion Biotech A/S$4.18+1.5%$3.57$2.82▼$18.50$21.82M-0.02531,819 shs25,104 shsLFLYLeafly$2.04+4.6%$2.84$1.90▼$16.00$4.69M1.0643,667 shs65,595 shsMTBCCareCloud$3.10$2.50▼$6.75$47.64M0.8563,000 shs66,900 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVTXAvalo Therapeutics+6.41%+37.06%+235.58%+258.20%-97.80%EVAXEvaxion Biotech A/S+1.46%-3.02%+39.33%-43.36%-67.34%LFLYLeafly+4.62%-5.99%-32.67%-55.46%-68.61%MTBCCareCloud0.00%0.00%0.00%0.00%0.00%The Best AI Stock to Own in the World Today is Trading for Just $25 (Ad)“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside himMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVTXAvalo TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AEVAXEvaxion Biotech A/S1.7335 of 5 stars3.53.00.00.00.61.70.6LFLYLeafly1.5554 of 5 stars3.33.00.00.02.90.80.0MTBCCareCloudN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVTXAvalo Therapeutics2.50Moderate BuyN/AN/AEVAXEvaxion Biotech A/S3.00Buy$11.00163.16% UpsideLFLYLeafly2.50Moderate Buy$6.00194.12% UpsideMTBCCareCloudN/AN/AN/AN/ACurrent Analyst RatingsLatest MTBC, LFLY, AVTX, and EVAX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/16/2024AVTXAvalo TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform4/3/2024EVAXEvaxion Biotech A/SHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.004/2/2024EVAXEvaxion Biotech A/SLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$8.004/1/2024LFLYLeaflyBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $6.003/20/2024EVAXEvaxion Biotech A/SHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.002/12/2024EVAXEvaxion Biotech A/SHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$14.00(Data available from 4/27/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVTXAvalo Therapeutics$1.92M8.55N/AN/A$9.11 per share1.75EVAXEvaxion Biotech A/S$70K311.71N/AN/A($1.17) per share-3.57LFLYLeafly$42.25M0.11N/AN/A($5.72) per share-0.36MTBCCareCloud$139.60M0.00N/A2.43$6.58 per share0.00Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVTXAvalo Therapeutics-$31.54M-$616.67N/AN/AN/A-1,639.50%-1,439.87%-113.95%5/2/2024 (Estimated)EVAXEvaxion Biotech A/S-$22.12M-$6.76N/A32.15N/AN/A-451.63%-149.27%5/29/2024 (Estimated)LFLYLeafly-$9.50M-$4.92N/A∞N/A-22.48%N/A-39.85%5/9/2024 (Confirmed)MTBCCareCloud$2.84M-$0.45N/AN/AN/A3.20%4.54%3.33%N/ALatest MTBC, LFLY, AVTX, and EVAX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2024N/ALFLYLeaflyN/AN/AN/AN/AN/AN/A 3/28/2024Q4 2023LFLYLeafly-$1.41-$0.22+$1.19-$0.22$9.49 million$9.75 million3/27/2024Q4 2023EVAXEvaxion Biotech A/SN/A-$0.16-$0.16-$0.16N/A$0.07 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVTXAvalo TherapeuticsN/AN/AN/AN/AN/AEVAXEvaxion Biotech A/SN/AN/AN/AN/AN/ALFLYLeaflyN/AN/AN/AN/AN/AMTBCCareCloudN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVTXAvalo TherapeuticsN/A1.821.82EVAXEvaxion Biotech A/SN/A1.181.18LFLYLeaflyN/A3.743.74MTBCCareCloudN/A1.211.19OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVTXAvalo Therapeutics87.06%EVAXEvaxion Biotech A/S11.04%LFLYLeafly15.55%MTBCCareCloud19.68%Insider OwnershipCompanyInsider OwnershipAVTXAvalo Therapeutics0.20%EVAXEvaxion Biotech A/S41.64%LFLYLeafly11.30%MTBCCareCloud34.90%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAVTXAvalo Therapeutics191.03 million1.03 millionNot OptionableEVAXEvaxion Biotech A/S635.22 million3.04 millionOptionableLFLYLeafly1302.30 million2.04 millionOptionableMTBCCareCloud4,10015.22 million9.91 millionNot OptionableMTBC, LFLY, AVTX, and EVAX HeadlinesSourceHeadlineCCLD Stock Earnings: CareCloud Beats EPS, Misses Revenue for Q4 2023investorplace.com - March 21 at 12:09 PMCareCloud (CCLD) Earnings Dates & Reportsinvesting.com - March 3 at 3:18 PMCareCloud, Inc. (NASDAQ:CCLD) Q2 2023 Earnings Call Transcriptfinance.yahoo.com - August 10 at 4:54 PMCareCloud Inc Preferred Series B (CCLDO)investing.com - May 17 at 2:50 PMRevenue Cycle Management Market Technologies, Size and Market ... - Cottonwood Holladay Journalnews.google.com - May 11 at 6:23 PMCareCloud CEO Hadi Chaudhry Named Finalist for Ernst & Young's ... - GlobeNewswirenews.google.com - May 11 at 6:23 PMHealthcare Cloud Computing Market Share In 2023 | Important ... - Digital Journalnews.google.com - May 11 at 8:22 AMPodiatry EMR Software Market Size Analysis Report 2023-2030 by ... - Digital Journalnews.google.com - May 11 at 8:22 AMCareCloud Wins Best Overall EHR Solution Provider in 2023 MedTech Breakthrough Awards - CareCloud (NASDAQ - Benzinganews.google.com - May 10 at 5:20 PMMorning Medical Update: New breast cancer screening guidelines ... - Medical Economicsnews.google.com - May 10 at 12:19 PM3 lessons the HealthTech industry can learn from CareCloud - Medical Economicsnews.google.com - May 10 at 12:19 PMCareCloud's Bill Korn, Chief Strategy Officer, and Joseph DosSantos ... - GlobeNewswirenews.google.com - May 9 at 11:01 AMCareCloud Strengthens Leadership Team with Key Transitions - GlobeNewswirenews.google.com - May 8 at 8:00 PMCareCloud CFO Bill Korn Named to New Role as Chief Strategy Officer - MarketWatchnews.google.com - May 8 at 3:00 PMWorkable Strategic Report on Medical Practice Management (PMS ... - Digital Journalnews.google.com - May 8 at 9:59 AMCareCloud appoints DosSantos as CFO, Korn as CSO - Seeking Alphanews.google.com - May 8 at 9:59 AMCareCloud Strengthens Leadership Team with Key Transitions - Yahoo Financenews.google.com - May 8 at 9:59 AMRecent Digital Health Strategic Partnerships Round Up - HIT Consultantnews.google.com - May 5 at 5:46 PMEF Hutton Reiterates CareCloud (CCLD) Buy Recommendation - Nasdaqnews.google.com - May 5 at 5:46 PMRising Trends of Emergency Medicine EMR Software Market will ... - Digital Journalnews.google.com - May 5 at 12:46 PMCareCloud Reports First Quarter 2023 Results - Yahoo Financenews.google.com - May 5 at 12:46 PMCareCloud Declares Dividends on Non-Convertible Series A and ... - InvestorsObservernews.google.com - May 5 at 12:46 PMGastroenterology EMR and Billing Software Market Size 2023 | New ... - Digital Journalnews.google.com - May 5 at 7:37 AMNexa Healthcare Announces Partnership with NexHealth to Offer 24 ... - EIN Newsnews.google.com - May 4 at 4:36 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAvalo TherapeuticsNASDAQ:AVTXAvalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation. The company's drug candidates include AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as Crohn's disease; Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome; and AVTX-008, a fully human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein. It also develops AVTX-803, a L-fucose monosaccharide therapy for treatment of Leukocyte Adhesion Deficiency Type II. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.Evaxion Biotech A/SNASDAQ:EVAXEvaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase 1/2a trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.LeaflyNASDAQ:LFLYLeafly Holdings, Inc. owns and operates a platform to provide consumers with cannabis information and connects consumers to cannabis brands and licensed retailers. The company offers subscription-based marketplace listings, digital advertising solutions, and software as a service-based tools to cannabis retailers; and information, reviews, menus, and ordering and delivery options to its audience through its website and mobile applications. Leafly Holdings, Inc. was founded in 2010 and is headquartered in Seattle, Washington.CareCloudNASDAQ:MTBCCareCloud, Inc. brings disciplined innovation to the business of healthcare. Our suite of technology-enabled solutions helps clients increase financial and operational performance, streamline clinical workflows, and make better business and care decisions. More than 40,000 providers across the United States count on CareCloud to help them improve patient care while reducing administrative burdens and operating costs. Services and solutions include revenue cycle management (RCM), practice management (PM), electronic health record (EHR), business intelligence, telehealth, and patient experience management (PXM). CareCloud is headquartered in Somerset, NJ. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.